{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:49:42Z","timestamp":1792651782787,"version":"4.5.0"},"reference-count":51,"publisher":"American Society of Hematology","issue":"23","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,6,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Prior studies suggest increased cytomegalovirus (CMV) infection after haploidentical donor transplantation with posttransplant cyclophosphamide (HaploCy). The role of allograft source and posttransplant cyclophosphamide (PTCy) in CMV infection is unclear. We analyzed the effect of graft source and PTCy on incidence of CMV infection, and effects of serostatus and CMV infection on transplant outcomes. We examined patients reported to the Center for International Blood and Marrow Transplantation Research between 2012 and 2017 who had received HaploCy (n = 757), matched related (Sib) with PTCy (SibCy, n = 403), or Sib with calcineurin inhibitor-based prophylaxis (SibCNI, n = 1605). Cumulative incidences of CMV infection by day 180 were 42%, 37%, and 23%, respectively (P &amp;lt; .001). CMV disease was statistically comparable. CMV infection risk was highest for CMV-seropositive recipients (R+), but significantly higher in PTCy recipients regardless of donor (HaploCy [n = 545]: hazard ratio [HR], 50.3; SibCy [n = 279]: HR, 47.7; SibCNI [n = 1065]: HR, 24.4; P &amp;lt; .001). D+\/R\u2212 patients also had increased risk for CMV infection. Among R+ or those developing CMV infection, HaploCy had worse overall survival and nonrelapse mortality. Relapse was unaffected by CMV infection or serostatus. PTCy was associated with lower chronic graft-versus-host disease (GVHD) overall, but CMV infection in PTCy recipients was associated with higher chronic GVHD (P = .006). PTCy, regardless of donor, is associated with higher incidence of CMV infection, augmenting the risk of seropositivity. Additionally, CMV infection may negate the chronic GVHD protection of PTCy. This study supports aggressive prevention strategies in all receiving PTCy.<\/jats:p>","DOI":"10.1182\/blood.2020009362","type":"journal-article","created":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T16:34:08Z","timestamp":1614789248000},"page":"3291-3305","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":185,"title":["Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis"],"prefix":"10.1182","volume":"137","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9216-2418","authenticated-orcid":false,"given":"Scott R.","family":"Goldsmith","sequence":"first","affiliation":[{"name":"Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis MO;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Bilal","family":"Abid","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology and"},{"name":"Division of Infectious Diseases, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffery J.","family":"Auletta","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplant Program and"},{"name":"Host Defence Program, Division of Hematology\/Oncology\/Bone Marrow Transplant\u2013Infectious Diseases, Nationwide Children's Hospital, Columbus, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asad","family":"Bashey","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplant Program, Northside Hospital, Atlanta, GA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer","family":"Beitinjaneh","sequence":"additional","affiliation":[{"name":"Division of Transplantation and Cellular Therapy, University of Miami, Miami, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Castillo","sequence":"additional","affiliation":[{"name":"UF Health Shands Children's Hospital, Gainesville, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy F.","family":"Chemaly","sequence":"additional","affiliation":[{"name":"MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Chen","sequence":"additional","affiliation":[{"name":"Center for International Blood and Marrow Transplantation Research (CIBMTR), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8597-3271","authenticated-orcid":false,"given":"Stefan","family":"Ciurea","sequence":"additional","affiliation":[{"name":"Stem Cell Transplant and Cellular Therapies Service, University of California, Irvine, Orange, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4001-9203","authenticated-orcid":false,"given":"Christopher E.","family":"Dandoy","sequence":"additional","affiliation":[{"name":"Cincinnati Children's Hospital Medical Center, University of Cincinnati School of Medicine, Cincinnati, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel \u00c1ngel","family":"D\u00edaz","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Hospital Infantil Universitario Ni\u00f1o Jesus, Madrid, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ephraim","family":"Fuchs","sequence":"additional","affiliation":[{"name":"The Sidney Kimmel Comprehensive Cancer Center, John Hopkins, Baltimore, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddhartha","family":"Ganguly","sequence":"additional","affiliation":[{"name":"Division of Hematological Malignancy and Cellular Therapeutics, University of Kansas Health System, Kansas City, KS;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher G.","family":"Kanakry","sequence":"additional","affiliation":[{"name":"Experimental Transplantation and Immunotherapy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Kanakry","sequence":"additional","affiliation":[{"name":"Experimental Transplantation and Immunotherapy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1404-0575","authenticated-orcid":false,"given":"Soyoung","family":"Kim","sequence":"additional","affiliation":[{"name":"Center for International Blood and Marrow Transplantation Research (CIBMTR), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI;"},{"name":"Division of Biostatistics, Institute of Health and Equity, Medical College of Wisconsin, Milwaukee, WI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna V.","family":"Komanduri","sequence":"additional","affiliation":[{"name":"Hematology, Oncology, University of Miami, Miami, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3980-480X","authenticated-orcid":false,"given":"Maxwell M.","family":"Krem","sequence":"additional","affiliation":[{"name":"Markey Cancer Center, University of Kentucky College of Medicine, Lexington, KY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1159-5607","authenticated-orcid":false,"given":"Hillard M.","family":"Lazarus","sequence":"additional","affiliation":[{"name":"University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3190-7807","authenticated-orcid":false,"given":"Hongtao","family":"Liu","sequence":"additional","affiliation":[{"name":"University of Chicago Medicine, Chicago, IL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8281-3245","authenticated-orcid":false,"given":"Per","family":"Ljungman","sequence":"additional","affiliation":[{"name":"Department of Cellular Therapy and Allogeneic Stem Cell Transplantation, Karolinska University Hospital Huddinge, and"},{"name":"Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Masiarz","sequence":"additional","affiliation":[{"name":"Adult Blood and Marrow Stem Cell Transplant Program, Knight Cancer Institute, Oregon Health and Science University, Portland, OR;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Mulroney","sequence":"additional","affiliation":[{"name":"University of California, San Diego Medical Center, La Jolla, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunita","family":"Nathan","sequence":"additional","affiliation":[{"name":"Section of Bone Marrow Transplant and Cell Therapy, Rush University Medical Center, Chicago, IL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2621-7924","authenticated-orcid":false,"given":"Taiga","family":"Nishihori","sequence":"additional","affiliation":[{"name":"Department of Blood & Marrow Transplant and Cellular Immunotherapy (BMT CI), Moffitt Cancer Center, Tampa, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin M.","family":"Page","sequence":"additional","affiliation":[{"name":"Division of Pediatric Blood and Marrow Transplantation, Duke University Medical Center, Durham, NC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5910-4571","authenticated-orcid":false,"given":"Miguel-Angel","family":"Perales","sequence":"additional","affiliation":[{"name":"Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6279-7567","authenticated-orcid":false,"given":"Randy","family":"Taplitz","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, City of Hope National Medical Center, Duarte, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rizwan","family":"Romee","sequence":"additional","affiliation":[{"name":"Stem Cell Transplantation Program, Dana Farber Cancer Institute, Boston, MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0257-0990","authenticated-orcid":false,"given":"Marcie","family":"Riches","sequence":"additional","affiliation":[{"name":"Center for International Blood and Marrow Transplantation Research (CIBMTR), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI;"},{"name":"Division of Hematology\/Oncology, The University of North Carolina at Chapel Hill, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,3,3]]},"reference":[{"key":"2021062208221487300_B1","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.3389\/fmicb.2019.01186","article-title":"Human cytomegalovirus latency and reactivation in allogeneic hematopoietic stem cell transplant recipients","volume":"10","author":"Stern","year":"2019","journal-title":"Front Microbiol"},{"issue":"11","key":"2021062208221487300_B2","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/j.bbmt.2012.05.015","article-title":"Efficacy of a viral load-based, risk-adapted, preemptive treatment strategy for prevention of cytomegalovirus disease after hematopoietic cell transplantation","volume":"18","author":"Green","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"2021062208221487300_B3","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.2217\/imt.15.70","article-title":"Therapeutic strategies for cytomegalovirus in allogeneic hematopoietic cell transplantation","volume":"7","author":"Nishihori","year":"2015","journal-title":"Immunotherapy"},{"issue":"1","key":"2021062208221487300_B4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2013.09.004","article-title":"Cytomegalovirus diseases after hematopoietic stem cell transplantation: a mini-review","volume":"342","author":"Ariza-Heredia","year":"2014","journal-title":"Cancer Lett"},{"issue":"1","key":"2021062208221487300_B5","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/cid\/civ215","article-title":"Reduced mortality of cytomegalovirus pneumonia after hematopoietic cell transplantation due to antiviral therapy and changes in transplantation practices","volume":"61","author":"Erard","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"19","key":"2021062208221487300_B6","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood.2019000956","article-title":"How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation","volume":"135","author":"Einsele","year":"2020","journal-title":"Blood"},{"issue":"20","key":"2021062208221487300_B7","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1182\/blood-2015-11-679639","article-title":"Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis","volume":"127","author":"Teira","year":"2016","journal-title":"Blood"},{"issue":"5","key":"2021062208221487300_B8","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1182\/blood-2010-08-304121","article-title":"Early cytomegalovirus replication after allogeneic stem cell transplantation is associated with a decreased relapse risk in acute myeloid leukemia patients: evidence for a putative virus-versus-leukemia effect","volume":"118","author":"Elmaagacli","year":"2011","journal-title":"Blood"},{"issue":"11","key":"2021062208221487300_B9","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1182\/blood-2011-10-386995","article-title":"Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function","volume":"119","author":"Foley","year":"2012","journal-title":"Blood"},{"issue":"7","key":"2021062208221487300_B10","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1182\/blood-2013-02-487074","article-title":"CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia","volume":"122","author":"Green","year":"2013","journal-title":"Blood"},{"issue":"11","key":"2021062208221487300_B11","doi-asserted-by":"crossref","first-page":"e465","DOI":"10.3324\/haematol.2016.149880","article-title":"Cytomegalovirus viremia, disease, and impact on relapse in T-cell replete peripheral blood haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide","volume":"101","author":"Goldsmith","year":"2016","journal-title":"Haematologica"},{"issue":"3","key":"2021062208221487300_B12","doi-asserted-by":"crossref","first-page":"S375","DOI":"10.1016\/j.bbmt.2015.11.887","article-title":"viral reactivation in haploidentical transplants using post-transplantation cyclophosphamide: a single institution experience","volume":"22","author":"Ramlal","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2021062208221487300_B13","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/infdis\/jit475","article-title":"High rate of cytomegalovirus drug resistance among patients receiving preemptive antiviral treatment after haploidentical stem cell transplantation","volume":"209","author":"Shmueli","year":"2014","journal-title":"J Infect Dis"},{"issue":"July","key":"2021062208221487300_B14","first-page":"1","article-title":"Haploidentical haematopoietic stem cell transplantation: role of NK cells and effect of cytomegalovirus infections","volume":"395","author":"Della Chiesa","year":"2015","journal-title":"Curr Top Microbiol Immunol"},{"issue":"2","key":"2021062208221487300_B15","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.bbmt.2017.09.018","article-title":"Prevention of cytomegalovirus reactivation in haploidentical stem cell transplantation","volume":"24","author":"Hammerstrom","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"25","key":"2021062208221487300_B16","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N Engl J Med"},{"issue":"19","key":"2021062208221487300_B17","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1309533","article-title":"Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation","volume":"370","author":"Chemaly","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"2021062208221487300_B18","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.bbmt.2018.09.038","article-title":"A randomized, double-blind, placebo-controlled phase 3 trial of oral brincidofovir for cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplantation","volume":"25","author":"Marty","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2021062208221487300_B19","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41409-019-0547-8","article-title":"Post-transplant cyclophosphamide use in matched HLA donors: a review of literature and future application","volume":"55","author":"El Fakih","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"suppl 1","key":"2021062208221487300_B20","article-title":"Post-transplantation cyclophosphamide after allogeneic hematopoietic stem cell transplantation: results of the prospective Randomized HOVON-96 trial in recipients of matched related and unrelated donors [abstract]","volume":"134","author":"De Jong","year":"2019","journal-title":"Blood"},{"issue":"3","key":"2021062208221487300_B21","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1016\/S2352-3026(18)30221-7","article-title":"Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)","volume":"6","author":"Bola\u00f1os-Meade","year":"2019","journal-title":"Lancet Haematol"},{"issue":"16","key":"2021062208221487300_B22","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1182\/blood-2009-11-251595","article-title":"High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease","volume":"115","author":"Luznik","year":"2010","journal-title":"Blood"},{"issue":"211","key":"2021062208221487300_B23","doi-asserted-by":"crossref","first-page":"211ra157","DOI":"10.1126\/scitranslmed.3006960","article-title":"Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide","volume":"5","author":"Kanakry","year":"2013","journal-title":"Sci Transl Med"},{"issue":"13","key":"2021062208221487300_B24","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1182\/blood-2013-10-525873","article-title":"Donor CD4+ Foxp3+ regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice","volume":"124","author":"Ganguly","year":"2014","journal-title":"Blood"},{"issue":"6","key":"2021062208221487300_B25","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2021062208221487300_B26","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1172\/JCI124218","article-title":"Post-transplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression","volume":"129","author":"Wachsmuth","year":"2019","journal-title":"J Clin Invest"},{"key":"2021062208221487300_B27","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.3389\/fimmu.2019.02668","article-title":"Mechanisms of graft-versus-host disease prevention by post-transplantation cyclophosphamide: an evolving understanding","volume":"10","author":"Nunes","year":"2019","journal-title":"Front Immunol"},{"issue":"suppl 1","key":"2021062208221487300_B28","doi-asserted-by":"crossref","first-page":"S485","DOI":"10.1093\/ofid\/ofy210.1387","article-title":"Hematopoietic cell transplantation with post-transplant cyclophosphamide: impact of donor type on pre-engraftment blood-stream infections","volume":"5","author":"Oltolini","year":"2018","journal-title":"Open Forum Infect Dis"},{"issue":"suppl 15","key":"2021062208221487300_B29","doi-asserted-by":"crossref","first-page":"e18533","DOI":"10.1200\/JCO.2019.37.15_suppl.e18533","article-title":"CMV reactivation in allogeneic hematopoietic stem cell transplant patients receiving post-transplant cyclophosphamide","volume":"37","author":"Markowski","year":"2019","journal-title":"J Clin Oncol"},{"issue":"3","key":"2021062208221487300_B30","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.bbmt.2018.10.011","article-title":"Cytomegalovirus infection incidence and risk factors across diverse hematopoietic cell transplantation platforms using a standardized monitoring and treatment approach: a comprehensive evaluation from a single institution","volume":"25","author":"Melendez-Munoz","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"2021062208221487300_B31","author":"CIBMTR forms instruction manual; Q428-440: infection","year":"2020"},{"issue":"1","key":"2021062208221487300_B32","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/cid\/ciw668","article-title":"Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials","volume":"64","author":"Ljungman","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2021062208221487300_bib51","article-title":"Statistical methods for time-dependent variables in hematopoietic cell transplantation studies [published online ahead of print 2 October 2020]","author":"Kim","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2021062208221487300_B33","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/BF00985764","article-title":"Score test of homogeneity for survival data","volume":"1","author":"Commenges","year":"1995","journal-title":"Lifetime Data Anal"},{"issue":"8","key":"2021062208221487300_B34","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.bbmt.2020.04.013","article-title":"Current use of and trends in hematopoietic cell transplantation in the United States","volume":"26","author":"D\u2019Souza","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2021062208221487300_B35","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/ejh.13204","article-title":"Haploidentical transplantation using low-dose alemtuzumab: comparison with haploidentical transplantation using low-dose thymoglobulin","volume":"102","author":"Kako","year":"2019","journal-title":"Eur J Haematol"},{"issue":"5","key":"2021062208221487300_B36","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s12185-010-0597-6","article-title":"Immune reconstitution and cytomegalovirus infection after allogeneic stem cell transplantation: the important impact of in vivo T cell depletion","volume":"91","author":"Schmidt-Hieber","year":"2010","journal-title":"Int J Hematol"},{"issue":"9487","key":"2021062208221487300_B37","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0140-6736(05)66996-6","article-title":"Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial","volume":"366","author":"Wagner","year":"2005","journal-title":"Lancet"},{"issue":"1","key":"2021062208221487300_B38","first-page":"78","article-title":"Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation","volume":"91","author":"Ljungman","year":"2006","journal-title":"Haematologica"},{"issue":"9","key":"2021062208221487300_B39","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1182\/blood-2002-03-0701","article-title":"Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders","volume":"100","author":"P\u00e9rez-Sim\u00f3n","year":"2002","journal-title":"Blood"},{"issue":"11","key":"2021062208221487300_B40","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.bbmt.2008.09.001","article-title":"The effect of in vivo T cell depletion with alemtuzumab on reduced-intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia","volume":"14","author":"Delgado","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"2021062208221487300_B41","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/bmt.2016.89","article-title":"Impact of early CMV reactivation in cord blood stem cell recipients in the current era","volume":"51","author":"Ramanathan","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"2021062208221487300_B42","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1093\/cid\/ciz490","article-title":"A mortality analysis of letermovir prophylaxis for cytomegalovirus (CMV) in CMV-seropositive recipients of allogeneic hematopoietic cell transplantation","volume":"70","author":"Ljungman","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"19","key":"2021062208221487300_B43","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1182\/blood-2013-05-499830","article-title":"CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT","volume":"122","author":"Schmidt-Hieber","year":"2013","journal-title":"Blood"},{"issue":"8","key":"2021062208221487300_B44","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1182\/blood-2015-04-639831","article-title":"Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia","volume":"126","author":"Ciurea","year":"2015","journal-title":"Blood"},{"issue":"9","key":"2021062208221487300_B45","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.bbmt.2010.03.020","article-title":"Evidence for a bidirectional relationship between cytomegalovirus replication and acute graft-versus-host disease","volume":"16","author":"Cantoni","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"2021062208221487300_B46","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/00007890-198411000-00004","article-title":"Cytomegalovirus infection associated with and preceding chronic graft-versus-host disease","volume":"38","author":"L\u00f6nnqvist","year":"1984","journal-title":"Transplantation"},{"issue":"3","key":"2021062208221487300_B47","doi-asserted-by":"crossref","first-page":"287","DOI":"10.5114\/ceji.2016.63129","article-title":"Immune recovery and the risk of CMV\/ EBV reactivation in children post allogeneic haematopoietic stem cell transplantation","volume":"41","author":"Janeczko","year":"2016","journal-title":"Cent Eur J Immunol"},{"issue":"4","key":"2021062208221487300_B48","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/01.TP.0000109778.39235.F4","article-title":"Reduced risk for extensive chronic graft-versus-host disease in patients receiving transplants with human leukocyte antigen-identical sibling donors given polymerase chain reaction-based preemptive therapy against cytomegalovirus","volume":"77","author":"Larsson","year":"2004","journal-title":"Transplantation"},{"issue":"4","key":"2021062208221487300_B49","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1097\/00007890-199602270-00014","article-title":"CD13-specific autoimmunity in cytomegalovirus-infected immunocompromised patients","volume":"61","author":"Soderberg","year":"1996","journal-title":"Transplantation"},{"key":"2021062208221487300_B50","doi-asserted-by":"crossref","first-page":"888","DOI":"10.3389\/fonc.2019.00888","article-title":"The presence of a CMV immunodominant allele in the recipient is associated with increased survival in CMV positive patients undergoing haploidentical hematopoietic stem cell transplantation","volume":"9","author":"Grosso","year":"2019","journal-title":"Front Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/137\/23\/3291\/1810581\/bloodbld2020009362.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/137\/23\/3291\/1810581\/bloodbld2020009362.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T04:23:34Z","timestamp":1624335814000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/137\/23\/3291\/475412\/Posttransplant-cyclophosphamide-is-associated-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,3]]},"references-count":51,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2021,3,3]]},"published-print":{"date-parts":[[2021,6,10]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2020009362","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,3]]}}}